Kazia Therapeutics Limited

NasdaqCM:KZIA Stock Report

Market Cap: US$12.7m

Kazia Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

John Friend

Chief executive officer

AU$1.3m

Total compensation

CEO salary percentage64.5%
CEO tenure1.6yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure2.4yrs

Recent management updates

Recent updates

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Jul 06

Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial

Jun 15

Enrollment gets underway in Kazia's mid-stage lymphoma study

Jun 07

Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer

Dec 10

Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study

Dec 09

Kazia stock +22% on positive paxalisib data in glioblastoma

Nov 18

CEO Compensation Analysis

How has John Friend's remuneration changed compared to Kazia Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$825k

-AU$27m

Mar 31 2024n/an/a

-AU$21m

Dec 31 2023n/an/a

-AU$16m

Sep 30 2023n/an/a

-AU$18m

Jun 30 2023AU$2mAU$743k

-AU$20m

Mar 31 2023n/an/a

-AU$23m

Dec 31 2022n/an/a

-AU$25m

Sep 30 2022n/an/a

-AU$25m

Jun 30 2022AU$1mAU$430k

-AU$25m

Compensation vs Market: John's total compensation ($USD796.22K) is about average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Friend (54 yo)

1.6yrs

Tenure

AU$1,279,844

Compensation

Dr. John Edwin Friend, II, M. D., serves as Chief Executive Officer at Kazia Therapeutics Limited since May 01, 2023 and since August 1, 2023 serves as Managing Director and Director and served as Chief Me...

Leadership Team

NamePositionTenureCompensationOwnership
John Friend
CEO, MD & Director1.6yrsAU$1.28mno data
Elissa Hansen
Company Secretaryless than a yearAU$48.01kno data
Jeffrey Bonacorda
VP of Finance & Controllerless than a yearno datano data

0.5yrs

Average Tenure

Experienced Management: KZIA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
John Friend
CEO, MD & Director1.3yrsAU$1.28mno data
Robert Apple
Non-Executive Directorless than a yearAU$39.30kno data
Bryce Carmine
Independent Non-Executive Chairman9.5yrsAU$95.42k0.20%
$ 24.9k
Patrick Wen
Member of Scientific Advisory Board2.4yrsno datano data
Steven Coffey
Independent Non-Executive Director12.1yrsAU$94.35k0.23%
$ 28.9k
Ebru Davidson
Independent Non-Executive Director1.5yrsAU$94.35kno data
Priscilla Brastianos
Member of Scientific Advisory Board2.4yrsno datano data
John de Groot
Member of Scientific Advisory Board2.4yrsno datano data
Alan Olivero
Member of Scientific Advisory Board2.4yrsno datano data

2.4yrs

Average Tenure

60.5yo

Average Age

Experienced Board: KZIA's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:08
End of Day Share Price 2024/12/26 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kazia Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Soo RomanoffEdison Investment Research
Swayampakula RamakanthH.C. Wainwright & Co.